Acurx Pharmaceuticals, Inc. (ACXP) vs Femasys Inc. (FEMY)
A side-by-side comparison of Acurx Pharmaceuticals, Inc. and Femasys Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACXP
Acurx Pharmaceuticals, Inc.
$1.29HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT
FEMY
Femasys Inc.
$2.08HealthcareDelayed quote: Oct 6, 2026, 10:28 AM EDT
Total return — ACXP vs FEMY
growth of $100 · dividends reinvested · last 5yACXP -99.2% (-61.6%/yr)FEMY -99.0% (-60.0%/yr)FEMY compounded faster over this window
ACXP FEMY
ACXP vs FEMY: by the numbers
- •FEMY is the larger company ($6M vs $6M market cap).
- •Both run net losses; ACXP's is the smaller (0.00% vs -534.27% net margin).
Metrics side by side
Valuation
| Metric | ACXP | FEMY |
|---|---|---|
| P/S ratio | N/A | 2.73 |
| P/B ratio | 0.68 | 1.56 |
Profitability
| Metric | ACXP | FEMY |
|---|---|---|
| Gross margin | 0.00% | 61.96% |
| Operating margin | 0.00% | -763.90% |
| Net margin | 0.00% | -534.27% |
| ROE | -92.08% | -304.78% |
| ROIC | -94.08% | -209.05% |
Growth (annualized)
| Metric | ACXP | FEMY |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 12.97% |
| Total return CAGR (5Y) | -57.41% | -57.27% |
Frequently asked
- How have ACXP and FEMY total returns compared?
- Over the past 5 years, ACXP delivered -57.41% and FEMY delivered -57.27% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.